PREPOPIK (citric acid; magnesium oxide; sodium picosulfate) by Ferring Pharmaceuticals is metabolite: bis-(p-hydroxy-phenyl)-pyridyl-2-methane, bhpm, which acts directly on the colonic mucosa to stimulate colonic peristalsis. First approved in 2012.
Drug data last refreshed 33m ago · AI intelligence enriched 2w ago
PREPOPIK is an oral bowel preparation solution containing sodium picosulfate, magnesium oxide, and citric acid approved in 2012 for colon cleansing prior to colonoscopy. Sodium picosulfate metabolizes to BHPM, which stimulates colonic peristalsis, while magnesium citrate (formed in situ) acts as an osmotic agent to retain water in the GI tract. The dual-mechanism approach provides effective bowel evacuation with a lower fluid volume requirement.
Product is approaching loss of exclusivity with moderate competitive pressure (15 competitors), signaling a defensive commercial phase with likely team consolidation and shift toward cost management and brand loyalty initiatives.
metabolite: bis-(p-hydroxy-phenyl)-pyridyl-2-methane, BHPM, which acts directly on the colonic mucosa to stimulate colonic peristalsis. Magnesium oxide and citric acid react to create magnesium citrate in solution, which is an osmotic agent that causes water to be retained within the…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study Comparing the Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution With PREPOPIK® for Colon Cleansing in Preparation for Colonoscopy
Efficacy and Safety of Prepopik® in Children for Overall Colon Cleansing in Preparation for Colonoscopy
Worked on PREPOPIK at Ferring Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Patent cliff in ~2 years — expect lifecycle management and generic defense hiring
PREPOPIK offers limited current career growth due to zero linked job openings and approaching loss of exclusivity, making it a consolidating asset rather than an expanding opportunity. Roles on this product are transitional, focusing on defending market share and preparing for generic competition rather than driving innovation or market expansion.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/mo